Press Releases

NEW YORK, Nov. 18, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced that its CEO and President, Robb Knie will be at

SOUTH PLAINFIELD, N.J., Nov. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of a no-cost testing program for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic condition. Children with AADC deficiency fail to thrive and commonly don't  reach developmental milestones that include being able to hold up thei

ELMSFORD, N.Y., Nov. 18, 2019 /PRNewswire/ -- NanoVibron

VANCOUVER, British Columbia, Nov. 18, 2019 /PRNewswire/ -- Core One Labs Inc. (CSE: COOL), (OTCQX: CLABF), (Frankfurt: LD6, WKN: A14XHT) ("COOL" or the "Company") announces it has completed the acquisition of Rainy Daze Cannabis Corp ("Rainy Daze") by purchasing all issued and outstanding shares of Rainy Daze in exchange for

DALLAS, Nov. 18, 2019 /PRNewswire/ --Corporate HighlightsAcquired Enteris BioPharma, Inc. ("Enteris") a biotechnology company offering innovative formulation solutions utilizing its proprietary oral drug delivery technology, Peptelligence® Enteris to operate as an independent, wholly-owned subsidiary of

VANCOUVER, British Columbia, Nov. 18, 2019 /PRNewswire/ -- Pasha Brands Ltd. ("Pasha") (CSE: CRFT) (OTC: CRFTF), Canada's largest craft cannabis brand house, last month called for the complete expungements of cannabis records, and a review of post-legalization enforcement. In the wake of raids on the natio

NEW YORK, Nov. 18, 2019 /PRNewswire/ -- Many female athletes encounter higher concussion rates than their male counterparts, according to two studies conducted by researchers at Hospital for Special Surgery (HSS).

REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 18, 2019 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the completion of Phase 2 clinical trial enrollment of FCD105 for the treatment of moderate-to-severe acne vulgaris. The trial will evaluate the effic

NORTH CHICAGO, Ill., Nov. 18, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes of certain series issued by Allergan Finance, LLC ("Allergan Finance"), Allergan, Inc. ("Allergan Inc"), Alle

COLUMBUS, Ohio, Nov. 18, 2019 /PRNewswire/ -- CAS, a division of the American Chemical Society, announced today that leading contract research, development and manufacturing organization (CRO/CDMO) BioDuro